Background. Most published data on antiretroviral-drug resistance is generated from in vitro or in vivo studies of subtype B virus. However, this subtype is associated with !10% of HIV infections worldwide, and it is essential to explore subtype-specific determinants of drug resistance. One potential cause of the differences between subtypes is the synonymous codon usage at key resistance positions.
and N) and several subtypes within group M [3] . The genetic distances of those variants also affect the aminoacid primary sequence of the viral proteins. Although the pol region is most conserved at the amino-acid level, considerable variation at the nucleotide level can be noticed. Synonymous substitutions are more common than are nonsynonymous substitutions in this region, as a result of selective pressure to maintain sequence integrity for enzyme function. Well-recognized drug resistance-associated amino-acid changes within RT and protease (PR) regions usually require 1 or 2 nucleotide changes from the wild-type (wt) virus (International AIDS Society-USA [http://www.iasusa.org] and Los Alamos National Laboratory HIV Database [http: //hiv-web.lanl.gov]). We postulated that, at these positions, synonymous genetic differences between HIV-1 subtypes may underpin subtype-specific routes to resistance, in terms of new amino-acid residues and/or alternative codons. A recent example is the nonnucleoside RT inhibitor RT mutation V106M in sub-type C viruses found in Israel [4] . The existence of different codons for the same amino-acid residue may also generate a longer pathway to reach the mutant codon. The main objective of the present study was to evaluate this possibility by use of HIV-1 sequences of different subtypes from drug-naive and drug-experienced Brazilian patients.
PATIENTS AND METHODS

Sequences and patients.
We analyzed 104, 59, and 26 RT nucleotide sequences and 152, 61, and 33 PR nucleotide sequences from drug-naive individuals who were infected with subtype B, C, and F1 isolates, respectively, to deduce consensus subtype-specific codons. To detect codons used in drug resistance-related mutations (DRRMs) of isolates from drug-experienced patients, 170, 35, and 43 RT sequences and 102, 29, and 41 PR sequences of subtype B, C, and F1 isolates, respectively, were included in the analysis. All nucleotide sequences used in the analyses were previously generated, by our group, from HIV-infected Brazilian individuals [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
Sequence analyses. Nucleotide sequences were grouped by subtype assignment, as was determined in their respective studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , and by treatment status (drug naive or drug experienced), and they were aligned in ClustalW [23] . Codon usages of different subtypes were determined on sequences from drug-naive patients, by use of CODEML software (version 3.12; available at http://abacus.gene.ucl.ac.uk/software/paml.html) [24] . Nucleotide sequences were further translated for DRRM analysis, and their codons were investigated. Codons were manually compared and scored . The PR codons 30, 46, 48, 50, 82, 84,  and 90 and the RT codons 41, 44, 62, 65, 67, 69, 70, 74, 75,  77, 100, 103, 106, 108, 115, 116, 118, 151, 181, 184, 188, 190,  210 , 215, and 219 were analyzed. These codons are in agreement with the most recent review of the International AIDS Society USA consensus panel [25] . Comparisons of Brazilian subtype B viruses from treatment-exposed individuals with their global counterparts were conducted using sequences from the Stanford HIV Drug Resistance Database (available at: http://hivdb .stanford.edu [26] ).
Statistical comparisons. Correlations between HIV-1 subtypes and codon preferences or DRRM frequencies were performed using Fisher's exact test or the test. Comparison of 2 x drug-exposure times for patients infected with subtypes B and F1 was conducted by use of a 2-tailed Student's t test. All analyses were conducted using AnalyseIt! (Microsoft Excel).
RESULTS
Codon usage among different Brazilian HIV-1 subtypes.
To evaluate possible biases in codon preferences among different subtypes, we first generated consensus sequences from 152 PR and 104 RT sequences of subtype B isolates from drugnaive Brazilian patients. Of note, the Brazilian PR and RT consensus sequences differed from the global subtype B consensus sequences obtained from the Los Alamos National Laboratory HIV Database (available at: http://hiv-web.lanl.gov) only at position 63 of PR, where a leucine was substituted for a proline in 90 (59%) of the sequences, and at position 135 of RT, where the isoleucine residue was substituted for a threonine in 75 (72%) of the sequences. No other codon differences, including those associated with resistance (see the Patients and Methods section), were observed between these 2 consensus sequences.
Sequences that contained PR and RT regions of 88 subtype B, 52 subtype C, and 24 subtype F1 isolates recovered from drug-naive subjects were compared to evaluate differences in codon usage. Table 1 summarizes all codon frequencies for each amino-acid residue in the pol region of all 3 subtypes. The only major differences in codon preferences were for tyrosine residues, which were preferably encoded by the triplet TAC in subtype F1 but were encoded by TAT in subtypes B and C. Those differences were statistically significant when compared by use of tests ( ). Most amino-acid residues were 2 x P ! .001 also shown to differ with regard to codon frequencies, with statistical significance noted between different subtypes, but the most prevalent codons had the same frequencies (table 1) .
Codon usages at DRRMs. We postulated that genetic polymorphisms in PR and RT codons related to drug resistance could have an effect on distinct genetic barriers (i.e., the number and nature of mutational events) to DRRM acquisition in different HIV-1 subtypes. To assess this hypothesis, specific codons in DRRMs were compiled from PR and RT sequences from drug-naive subjects. and 1 ts are necessary to take subtype F1 codon CAA to ATG, whereas, for the remaining subtypes, only 2 tv are necessary (CAGrATG). Similarly, for the L210W mutation, 1 tv and 1 ts are necessary in subtype F1 viruses, whereas only 1 tv is required for other subtypes. All remaining wt codons showed the same evolutionary cost, in terms of the number and nature of nucleotide substitutions, to change to mutant codons in all 3 subtypes. These results suggest that a higher genetic barrier may play a role in some DRRM acquisition in the RT gene from different subtypes. For the PR coding region, although we could observe a difference at codon 48 in subtypes B and F1 (GGG), compared with subtype C (GGA), both wt codons needed 1 tv to get to the resistant amino-acid residue valine (GTG or GTA), and, thus, no extra evolutionary cost was observed.
Treatment-associated codon substitutions in Brazilian HIV-1 subtypes. We wanted to corroborate our theoretical predictions regarding codon substitution and genetic barriers in clinical samples obtained from treated HIV-infected patients. To accomplish this, we obtained 102, 41, and 29 PR nucleotide sequences of subtypes B, F1, and C, respectively, from protease inhibitor-experienced Brazilian patients [6, 8, 14, 15] , and we also obtained 170, 43, and 35 RT nucleotide sequences of subtypes B, F1, and C, respectively, from RT inhibitor-experienced Brazilian patients [5, 8, 14, 15] . In addition, we sampled, from the Stanford HIV Drug Resistance Database, ∼200 subtype B nucleotide sequences that harbored resistance mutations. All PR and RT DRRM positions had their codons examined and compiled for each subtype. Differences in codon usage were observed in the subtype B data set of the Stanford HIV Drug Resistance Database, compared with the Brazilian subtype B sequences from the present study. Although codon TTG was preferably used in both subtype B data sets for RT mutation M41L, the Brazilian data set used the alternative codon CTG more frequently ( ; Fisher's exact test) than did the P p .046 Stanford data set (data not shown). When codon preferences among all 3 subtypes observed were compared, most of the resistance codons were either the same or, if different, reflected the genetic pathway with the smallest evolutionary cost from their respective wt codons. For example, for RT mutation K70R, which has wt codon AAA for subtypes B and F1 and wt codon AAG for subtype C, the mutant codons are AGA and AGG, respectively. In some cases, however, the codon change with the least evolutionary cost is not taken. This is the case for RT codon K219, which is encoded by AAA in subtype B and F1 viruses and is encoded by AAG in subtype C viruses. When resistant strains were analyzed, subtype B isolates used the codon GAA (glutamic acid) (1 ts), whereas their subtype F1 counterparts preferably used codon GAG (2 ts) (table 3). This preference was statistically significant ( ; Fisher's exact test). P p .046 Prevalence of DRRMs in treated Brazilian patients. To determine whether a higher genetic barrier for the L210W mutation would hinder the evolution rate of this mutation, we calculated the frequency of the L210W mutation among 170 subtype B-infected patients and 43 subtype F1-infected patients who were receiving regimens that contained zidovudine or stavudine. The prevalence of the L210W mutation was higher in subtype B viruses (36%) than in their subtype F1 counterparts (7%) ( ; Fisher's exact test). Of interest, the lower prev-P ! .001 alence of the L210W mutation in subtype F1 viruses was correlated with a higher proportion of the K70R mutation (30%) in such viruses. In fact, when we considered only sequences that carried one or the other mutation, 40 (41%) of 98 subtype B sequences had the K70R mutation, and the remaining 58 subtype B sequences (59%) had the L210W mutation, whereas 12 (86%) of 14 subtype F1 sequences had the K70R mutation, and the remaining 2 subtype F1 sequences (14%) had the L210W mutation ( ; test). The average duration (‫ע‬SD) of 2 P p .002 x exposure to zidovudine and/or stavudine among the patients was months, for subjects infected with subtype B, and 41.5 ‫ע‬ 22.5 months, for subjects infected with subtype F1. These 50.2 ‫ע‬ 23.9 exposure times were not significantly different ( ; 2-tailed P p .194 Student's t test). The prevalence of the Q151M mutation in the sequences analyzed was too low for the assessment of HIV-1 subtype-specific patterns.
DISCUSSION
HIV-1 has a high prevalence of rare codons that are associated with a monotonous error bias from the RT enzyme. Different codon usages were found in different subtypes when the pol coding region was analyzed. Codon preferences can also lead to different mutational pathways for the accumulation of DRRM. The analyses in the present study showed that 2 drug resistance-related RT residues, 210 and 151, have a higher genetic barrier to the acquisition of the resistance codons in subtype F1, compared with subtypes B and C, both of which are important determinants of nucleoside analogue susceptibility [27] [28] [29] . It is noteworthy that these 2 resistance codons [W (14) AAT (3) AAT (2) M46I ATG ATA (13), ATT (2) ATA (6) ATA (2) M46L ATG TTG (7), TTA (1)
CTA (1) TTG (9), (6) AAC (18) AAC (1) T69D ACT GAT (8) GAT ( (TGG) and M (ATG)] are not degenerate and, therefore, underpinned the pathway to reach the mutant codon. The frequency of the L210W mutation was significantly lower among subtype F1-resistant isolates recovered from nucleoside reversetranscriptase inhibitor (NRTI)-treated HIV-1-infected individuals, compared with their subtype B-resistant and subtype Cresistant isolates ( ). The L210W, T215Y/F, and M41L P ! .001 mutations usually are positively associated in NRTI-resistant clinical isolates [27, 28] . Moreover, a negative correlation between the K70R and L210W mutations has been observed in subtype B isolates [30, 31] . An analysis of 12000 NRTI-treated subtype B isolates from the Stanford HIV Drug Resistance Database showed that approximately one-half the isolates carried 1 mutation, and approximately one-half carried the other mutation; however, only 5% of the isolates carried both mutations (data not shown). This finding is in agreement with the findings of crystallographic studies that suggested that L210W substitution stabilizes the interaction of T215F/Y substitution with the dNTP-binding pocket [30] . This interaction occurs close to the conserved D113 residue, with which the lateral chain of R70 can also interact. This situation can create a conformational hindrance around residue D113 [30] . When such a scenario is present, the higher genetic barrier for the emergence of the L210W mutation in our subtype F1 strains could promote the accumulation of the K70R mutation, which further prevents the establishment of the L210W mutation. In fact, we could show a higher K70R:L210W ratio in subtype F1-resistant clinical isolates, compared with subtype B isolates ( ). P ! .002 A similar type of genetic-barrier difference is likely to take place at position 151, where the wt codon in subtype B is CAG and its subtype F1 counterpart is CAA, yielding a longer pathway to the mutant codon ATG in the latter subtype. Because of the low frequency of the Q151M mutation in our data set, however, we could not perform any statistical analysis of its emergence in treated patients.
Apart from the L210W and Q151M mutations, the remaining drug-resistant substitutions in RT are specified by degenerate codons. Most of the PR and RT resistance codons either were the same in subtypes B, C, and F1 or were different but reflected the genetic pathway with the smallest evolutionary cost from their respective wt codons. However, in the case of mutation K219E, the codon change with the least evolutionary cost is not made in subtype F1, which preferably changes codon AAA (K) to GAG (E) (2 ts), rather than changing it to GAA (E) (1 ts).
The present study has provided the first piece of evidence that differential genetic barriers between subtypes B and F1 may lead to altered rates of emergence of DRRM at RT position 210. The low prevalence of the L210W mutation in subtype F1 isolates can have an important implication in rescue-therapy regimens in patients infected with this subtype. Subtypes F and C, which are also found in other parts of the world, cause distinct HIV/AIDS epidemics in different continents. The initial findings of the present study should be further investigated in association with other HIV-1 subtypes, to predict the level of genetic barriers, compared with subtype B. Preliminary analysis of 11 subtype F2 RT sequences obtained from the Los Alamos National Laboratory HIV Database has shown that subtype F2 does not present differences at codons Q151 and L210, compared with subtype B. This finding shows that even sub-subtype-specific patterns can be found to have an effect on drug resistance and should be examined in more detail.
Different HIV-1 subtypes seem to possess distinct potentials for DRRM acquisition, including alternative routes and substitutions. The data from the present study further strengthen this idea, which may affect the future design of antiretroviral regimens in distinct areas of the world where non-B isolates dominate the HIV/AIDS epidemic.
